Source: European Medicines Agency (EU) Revision Year: 2024 Publisher: STADA Arzneimittel AG, Stadastrasse 2–18, 61118 Bad Vilbel, Germany
Libmyris 80 mg solution for injection in pre-filled syringe.
| Pharmaceutical Form |
|---|
|
Solution for injection. Clear and colourless solution for injection. |
One 0.8 ml single dose pre-filled syringe contains 80 mg adalimumab.
Adalimumab is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary cells.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Adalimumab |
Adalimumab binds specifically to TNF and neutralizes the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC50 of 0.1-0.2 nM). |
| List of Excipients |
|---|
|
Sodium chloride |
0.8 ml preservative-free solution for injection in a pre-filled type I glass syringe with a fixed 29-gauge needle, extended finger flanges and needle guard, and a plunger stopper (bromobutyl rubber, latexfree).
Pack sizes: 1 pre-filled syringe packed in a PVC/PE blister, with 1 alcohol pad.
STADA Arzneimittel AG, Stadastrasse 2–18, 61118 Bad Vilbel, Germany
EU/1/21/1590/007
Date of first authorisation: 12 November 2021
| Drug | Countries | |
|---|---|---|
| LIBMYRIS | Austria, Estonia, France, Croatia, Ireland, Lithuania, Poland |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
